A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 26 Dec 2018 Planned End Date changed from 14 Nov 2020 to 14 Mar 2021.
- 26 Dec 2018 Planned primary completion date changed from 14 Nov 2020 to 14 Mar 2021.
- 24 Apr 2018 Planned primary completion date changed from 22 Oct 2019 to 14 Nov 2020.